VPT:CC - Ventripoint Welcomes Matt Dobson as Marketing Director to Guide Market Development and Product Management
(TheNewswire)
Toronto, Ontario – ThedNewswire - June 13, 2024 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"),(TSXV:VPT ) ; ( OTC:VPTDF) isdelighted to welcome Matt Dobson as the company's new MarketingDirector, to accelerate the company’s path to commercialization.
A seasoned professional in strategic marketing, Matt brings a wealthof experience from his tenure in various marketing roles andindustries, including medical technology, diagnostics, therapeutics,technology and fast-paced consumer goods.
Based in the U.K., Matt will focus on developing actionable productdevelopment, marketing and sales programs built upon proprietarymarket, customer and user insights and ensuring optimalproduct-customer fit.
“Matt has excelled in past assignments and will be key in evolvingVentripoint to becoming a market driven organization,” saidVentripoint’s CEO Hugh MacNaught. “Our focus is developingactionable insights on how to drive adoption of Ventripoint’stechnology in routine clinical practice”.
Added Dobson: “Ventripoint's proposition is unique, offering arevolutionary mix of accuracy, efficiency, and user-friendliness incardiac imaging using artificial intelligence. This affordable toolpromises to advance heart health management, making heart scans withcMRI levels of accuracy available to more people, at a fraction of thecost and with results in minutes.”
Dobson’s role begins immediately. His full bio is here ( )
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in the application of AI(Artificial Intelligence) to echocardiography. Ventripoint's VMSproducts are powered by its proprietary KBR technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
Forward Looking Statements
This news release contains forward-looking statements andforward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and information address future eventsand conditions, by their very nature they involve inherent risks anduncertainties. Actual results could differ materially from thosecurrently anticipated due to several factors and risks. Factors whichcould materially affect such forward-looking information are describedin the risk factors in the Company's most recent annual management'sdiscussion and analysis that is available on the Company's profile onSEDAR at www.sedar.com. Readers are cautioned that theforegoing list of factors is not exhaustive. The forward-lookingstatements included in this news release are expressly qualified bythis cautionary statement. The forward-looking statements andinformation contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.